Breast cancer is the most common malignancy among women affecting more than a million women per year worldwide. Hypoxia-Inducible Factor-1 (HIF-1) has an impact on metastasis by neovascularization.. In cancer cells, hypoxia activates a complex cell signaling network, including the HIF, PI3K, MAPK, and NFB pathways, which interact to create positive and negative feedback loops, enhancing or diminishing hypoxic effects. The present research introduces a novel bio-reductive Co(III)-based prodrug, which can release multiple FDA-approved cytotoxins like melphalan, doxorubicin, or RS-130830 (MMP inhibitor) along with a cell-permeable, hydroxyquinoline HIF Prolyl Hydroxylase (PHD) inhibitor selectively only in hypoxic tumors. Two electron reduction of the proposed model was based on the thiol-induced reduction of Co(III) into The model is hypothesized to enhance the efficacy of multiple chemotherapeutic drugs for targeting specific antitumor activity in hypoxic breast cancer cells without affecting the normal tissue and efficiently circumvent present challenges with bio-reductive prodrugs and chemotherapeutic drugs. In hypoxic breast cancer, altered GLUT1, VEGF1, and HIF1 expression have been linked to a higher risk of recurrence, higher-grade tumors, and proliferation. The discovery of new therapeutics targeting hypoxic tumor cells and the hypoxic microenvironment will  help by a deeper understanding of the function of hypoxia in breast cancer progression and metastasis.

Dr. Sukhes Mukherjee is working as Additional Professor in Biochemistry Department of AIIMS Bhopal. He is a committed and hard-working faculty member involved in teaching and in research for the last 17 years. He has a very active academic and research career. He has published more than 104 papers in peer-reviewed journals. He has also presented his work at several national and international conferences. He got the best paper award from the“Association of Clinical Biochemists of India” in 2008. He got the international travel fellowship to attend the Neurochemistry conference at Busan, South Korea in August 2009 and another AACC fellowship in 2011. He is regularly giving training on behalf of his department to undergraduate and postgraduate medical students and himself getting training in the cutting-edge technologies of advancement in the field of Advanced Biology, Biochemistry and Molecular biology. Recently he was awarded fellowship of 230 years old Linnean Society, UK and also inducted as Member of National Academy of Medical Sciences, India (MAMS) in 2020 and Royal Society of Public Health, UK. He is also an elected fellow of the Royal Society of Medicine (U.K). His research interest is Clinical Biochemistry, Precision Oncology and Biochemical Insights to Metabolic diseases.